<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81184</article-id><article-id pub-id-type="doi">10.7554/eLife.81184</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-284520"><name><surname>Farrell</surname><given-names>Mariah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-283559"><name><surname>Fairfield</surname><given-names>Heather</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8852-2254</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284521"><name><surname>Karam</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284522"><name><surname>D'Amico</surname><given-names>Anastasia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284523"><name><surname>Murphy</surname><given-names>Connor S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284524"><name><surname>Falank</surname><given-names>Carolyne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284525"><name><surname>Pistofidi</surname><given-names>Romanos Sklavenitis</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284526"><name><surname>Cao</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284527"><name><surname>Marinac</surname><given-names>Catherine R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-284528"><name><surname>Dragon</surname><given-names>Julie A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284529"><name><surname>McGuinness</surname><given-names>Lauren</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284534"><name><surname>Gartner</surname><given-names>Carlos G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284530"><name><surname>Iorio</surname><given-names>Reagan Di</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284531"><name><surname>Jachimowicz</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284532"><name><surname>DeMambro</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284533"><name><surname>Vary</surname><given-names>Calvin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-284535"><name><surname>Reagan</surname><given-names>Michaela R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2884-6481</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Center for Molecular Medicine</institution>, <institution>Maine Health Institute for Research</institution>, <addr-line><named-content content-type="city">Scarborough</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Center for Molecular Medicine</institution>, <institution>Maine Medical Center Research Institute</institution>, <addr-line><named-content content-type="city">Scarborough</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution>University of New England</institution>, <addr-line><named-content content-type="city">Biddeford</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-190571"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing editor</role><aff><institution>DaVita Labs</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Michaela.Reagan@MaineHealth.org</email> (MR);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e81184</elocation-id><history><date date-type="received"><day>17</day><month>06</month><year>2022</year></date><date date-type="accepted"><day>13</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Farrell et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Farrell et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81184-v1.pdf"/><abstract><p>Multiple myeloma is an incurable plasma cell malignancy with only a 53% 5-year survival rate. There is a critical need to find new multiple myeloma vulnerabilities and therapeutic avenues. Herein, we identified and explored a novel multiple myeloma target: the fatty acid binding protein (FABP) family. In our work, myeloma cells were treated with FABP inhibitors (BMS3094013 and SBFI-26) and examined <italic>in vivo</italic> and <italic>in vitro</italic> for cell cycle state, proliferation, apoptosis, mitochondrial membrane potential, cellular metabolism (oxygen consumption rates and fatty acid oxidation), and DNA methylation properties. Myeloma cell responses to BMS309403, SBFI-26, or both, were also assessed with RNA sequencing (RNA-Seq) and proteomic analysis, and confirmed with western blotting and qRT-PCR. Myeloma cell dependency on FABPs was assessed using the Cancer Dependency Map (DepMap). Finally, MM patient datasets (CoMMpass and GEO) were mined for <italic>FABP</italic> expression correlations with clinical outcomes. We found that myeloma cells treated with FABPi or with <italic>FABP5</italic> knockout (generated via CRISPR/Cas9 editing) exhibited diminished proliferation, increased apoptosis, and metabolic changes <italic>in vitro</italic>. FABPi had mixed results <italic>in vivo</italic>, in two pre-clinical MM mouse models, suggesting optimization of <italic>in vivo</italic> delivery, dosing, or type of FABP inhibitors will be needed before clinical applicability. FABPi negatively impacted mitochondrial respiration and reduced expression of MYC and other key signaling pathways in MM cells <italic>in vitro</italic>. Clinical data demonstrated worse overall and progression-free survival in patients with high <italic>FABP5</italic> expression in tumor cells. Overall, this study establishes the FABP family as a potentially new target in multiple myeloma. In MM cells, FABPs have a multitude of actions and cellular roles that result in the support of myeloma progression. Further research into the FABP family in MM is warrented, especially into the effective translation of targeting these <italic>in vivo</italic>.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA257695</award-id><principal-award-recipient><name><surname>Murphy</surname><given-names>Connor S</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R37CA245330</award-id><principal-award-recipient><name><surname>Reagan</surname><given-names>Michaela R</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R50CA265331</award-id><principal-award-recipient><name><surname>Fairfield</surname><given-names>Heather</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>P20GM103449</award-id><principal-award-recipient><name><surname>Dragon</surname><given-names>Julie A</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>U54GM115516</award-id><principal-award-recipient><name><surname>Reagan</surname><given-names>Michaela R</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>P20GM121301</award-id><principal-award-recipient><name><surname>Vary</surname><given-names>Calvin</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>P20GM121301</award-id><principal-award-recipient><name><surname>Reagan</surname><given-names>Michaela R</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>RSG-19-037-01-LIB</award-id><principal-award-recipient><name><surname>Reagan</surname><given-names>Michaela R</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>IRG-16-191-33</award-id><principal-award-recipient><name><surname>Reagan</surname><given-names>Michaela R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Catherine R Marinac, GRAIL Inc: Research Funding; JBF Legal: Consultancy..</p></fn><fn fn-type="conflict" id="conf3"><p>Michaela R Reagan, Reviewing editor, <italic>eLife</italic>Oncopeptides Inc, SynDevRx Inc: Research Funding..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experimental studies and procedures involving mice were performed in accordance with approved protocols from the Maine Medical Center Research Institute's (Scarborough, Maine, USA) Institutional Animal Care and Use Committee (protocols #2111 or #1812).</p></fn><fn fn-type="other"><p>Human subjects: Primary human MSCs were isolated from deidentified cancellous bone from the acetabulum received from donors (men and women) after total hip arthroplasty through the MaineHealth Biobank after IRB approval and informed consent (Biobank IRB # 2526).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The clinical datasets used and analyzed during the current study are from Oncomine or data related to accession number GEO:GSE6477. RNA-seq data have been deposited in the NCBI Gene Expression Omnibus (GEO) database with the accession number GSE190699. The mass spectrometry proteomic data have been deposited to the ProteomeXchange Consortium via the PRIDE partner respository with the dataset identifier PXD032829.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Farrell M</collab><collab>Fairfield H</collab><collab>Karam M</collab><collab>D'amico A</collab><collab>Murphy CS</collab><collab>Falank C</collab><collab>Pistofidis RS</collab><collab>Cao A</collab><collab>Marinac CR</collab><collab>Dragon J</collab><collab>McGuinness L</collab><collab>Gartner C</collab><collab>Iorio RD</collab><collab>Jachimowicz E</collab><collab>DeMambro V</collab><collab>Vary C</collab><collab>Reagan MR</collab></person-group><year iso-8601-date="2022">2022</year><source>The Fatty Acid Binding Protein Family Represents a Novel Target in Multiple Myeloma</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190699">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190699</ext-link><comment>NCBI Gene Expression Omnibus, GSE190699</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Farrell M</collab><collab>Fairfield H</collab><collab>Karam M</collab><collab>D'amico A</collab><collab>Murphy CS</collab><collab>Falank C</collab><collab>Pistofidis RS</collab><collab>Cao A</collab><collab>Marinac CR</collab><collab>Dragon J</collab><collab>McGuinness L</collab><collab>Gartner C</collab><collab>Iorio RD</collab><collab>Jachimowicz E</collab><collab>DeMambro V</collab><collab>Vary C</collab><collab>Reagan MR</collab></person-group><year iso-8601-date="2023">2023</year><source>The Fatty Acid Binding Protein Family Represents a Novel Target in Multiple Myeloma</source><ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD032829">http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD032829</ext-link><comment>ProteomeXchange Consortium, PXD032829</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Chng WJ</collab><collab>Kumar S</collab><collab>Vanwier S</collab><collab>Ahmann G et al.</collab></person-group><year iso-8601-date="2006">2006</year><source>Expression data from different stages of plasma cell neoplasm</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi</ext-link><comment>NCBI Gene Expression Omnibus, GSE6477</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-81184-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>